|
|
Biography |
|
|
Dr. Kilama has tremendous amount of international experience with great focuses on Africa and other developing countries, particularly as it pertains to promotion of private/public partnerships for research, trade, technology transfer, healthcare, and intellectual property.
As the Founder and Director of Global Bioscience Development Institute (GBDI), Dr. Kilama initiated and supervised innovative initiatives in Africa and the US that strengthened direct foreign investments and launched strategies to increase economic development. Currently, as Founder and Director of the Kilama International Consulting Group (KICG), he forwards the mission to manage IPR in developing countries.
He possesses a unique combination of experience across industry and non-governmental organizations, with analytical expertise in international trade regulations and economic impact on developing nations.
Dr. Kilama endeavors to enhance understanding and insight of developing countries’ governments, understanding industry’s needs, public health issues, and potential benefits of private/public partnerships for development of medicines, agricultural products, and use of traditional knowledge. A creator/developer of effective advanced training, his programs have educated over 700 executives and policymakers from 45 countries, including 39 in Africa. His Intellectual Property training has been applied to policy and regulation development in various countries and institutions. Training attendees have represented major corporations including Monsanto, DuPont, Dow, Aventis, Syngenta, Pioneer, Diversa, Bayer, USAID, AfricaBio, UNDP, UNEP, and others.
Dr. Kilama’s professional affiliations include, but are not limited to, the World Health Organization (WHO), Children’s Hospital of Philadelphia (CHOP), Medicines 360, Public Interest Intellectual Property Advisors (PIIPA), The Institute of Trade, Standards, and Sustainable Development (IOTSSD), and George Washing University Law School’s Creative and Innovation Economy Center.
He has extensive leadership and public relations experience as an international conference presenter, founding board member, advisory board member, and senior advisory board member across non-profit companies, private partnerships, global health initiatives, and international organizations.
Dr. Kilama has authored numerous scientific publications and op-eds, and has completed several Trade Missions.
|
|
|
|
|
|
|
Abstract |
|
|
|
|
|
|
|
|
Metabolomics is a new technology that is primarily focusing on a comprehensive characterization of small molecule metabolites using a variety of technologies such as nuclear magnetic resonance, liquid chromatography and/or mass spectrometry.
Because metabolomics concepts overlap with many aspects of pharmaceutical research, there are now many applications that intersect with a full array of the drug discovery and development pipeline, from lead compound discovery to post-approval drug surveillance. In additions, metabolomics potentially offer drug researchers and drug regulators a cheaper way to tackle the riskier or more costly process issues related to discovery, development and post marketing monitoring of drug products.
In my presentation, I will discuss how metabolomics is becoming an important tools for Natural Product Discovery.
|
|
|
|
|